Drug intelligence / Profile preview

hyaluronic acid + lidocaine (Medytox Inc.)

Development stage
Unknown
Lead developer
Medytox
Administration
Subcutaneous, Intradermal
01

Overview

Neuramis Volume Lidocaine is a hyaluronic acid-based dermal filler developed by Medytox. It is classified as a medical device and consists of cross-linked hyaluronic acid (20 mg/mL) combined with 0.3% lidocaine for pain reduction during injection. The filler is produced using Medytox's proprietary SHAPE (Stabilized Hyaluronic Acid Purification Enhancement) technology, which employs a two-step cross-linking process to ensure high purity and minimal residual cross-linking agents like BDDE (butanediol diglycidyl ether). It is specifically designed for deep facial volumization, including mid-face volume restoration, cheek and chin augmentation, and the correction of deep facial folds. The effects typically persist for 6 to 18 months, and the product utilizes FDA-approved hyaluronic acid and is certified by the European Directorate for the Quality of Medicines (EDQM).

Brand names
Neuramis Volume Lidocaine
Other names
Neuramis VolumeNeuramis Lidocaine
02

Targets

ICAM1 (Intercellular Adhesion Molecule 1)RHAMM (Hyaluronan-mediated motility receptor)LYVE1 (Lymphatic vessel endothelial hyaluronic acid receptor 1)CD44 (CD44 antigen)STAB2 (Stabilin-2)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on hyaluronic acid + lidocaine (Medytox Inc.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hyaluronic acid + lidocaine (Medytox Inc.).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call